Navitoclax-encapsulated dual pH-responsive copolymeric nanoparticles improves hepatocellular carcinoma treatment with induction of apoptosis and immune activation
FPNAI enhances the antitumor activity of navitoclax by integrating targeted drug delivery, reactive oxygen species–mediated mitochondrial apoptosis, and immunogenic cell death induction, and the proposed nanotherapeutic platform represents a promising approach for improving hepatocellular carcinoma treatment outcomes.